UKidney Nephrology News and Insights

UKidney Renal Week 2019 Update Banner

We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the...

UKidney Renal Week 2019 Update Banner

We are pleased to announce our collaboration with ConferenceInsider™ to bring you on-site coverage of ASN Kidney Week 2019 from our nation's capital. We'll bring you the heart of ASN Kidney Week 2019, from November 7 - 11, 2019. This is your direct connection to the most trusted and clinically relevant information about recent advances in the field of nephrology.

We'll continue to post educational session summaries and interviews with key opinion leaders throughout the conference – delivering the latest developments in nephrology medicine and patient care right to your email inbox. We want to hear from you, too. So be sure to share your opinions through our insightful daily polls.

If you’re not signed up already, please subscribe to UKidney to receive daily emails throughout ASN Kidney Week 2019. Each email will directly link to posted session updates. We hope you enjoy this resource!

The UKidney & ConferenceInsider Teams

More
NOV
09
0

Effect of angiotensin-neprilysin inhibition on renal outcomes in heart failure with preserved ejection fraction

Session: High-Impact Clinical Trials

Presenter: Finnian R. McCausland, MBBCh, MMSc, FRCPI, PG CertMedEd, Assistant Professor, Harvard Medical School

Dr. Danielle KirkmanFinnian R. McCausland

Looking out to a booked-solid room, Finnian R. McCausland, MBBCh, relayed the results of a trial concerning the effects of angiotensin-neprilysin inhibition on renal outcomes in patients with preserved ejection fraction.

Continue reading
NOV
09
0

Pooled efficacy and cardiovascular (CV) analyses of roxadustat in the treatment of anemia in CKD patients on and not on dialysis

Session: High-Impact Clinical Trials

Presenter: Robert Provenzano, MD, FACP, FASN, Chief Medical Officer, Nephrology Practice Solutions & Vice President, Medical Affairs

Before a packed crowd, Robert Provenzano, MD, FASM, DaVita Healthcare, presented pooled efficacy and cardiovascular (CV) safety analyses from the pivotal Phase III program assessing roxadustat for the treatment of patients with anemia from chronic kidney disease (CKD).

Continue reading
NOV
08
0

Racial/ethnic disparities in atrial fibrillation treatment and outcomes in us dialysis patients

Poster: Racial/Ethnic Disparities in Atrial Fibrillation Treatment and Outcomes in US Dialysis Patients

Presenter: Adan Z. Becerra PhD, Social & Scientific Systems

Authors: Paul L. Kimmel, MD, FASN, National Institute of Diabetes and Digestive Kidney Diseases (NIDDK), Salina Paulette Waddy, MD, Atlanta Veterans Administration, Allen J. Solomon, MD, The George Washington University, Adan Z. Becerra PhD, Social & Scientific Systems, Julia B. Ward, PhD, MPH, Social & Scientific Systems, Inc., Kevin Chan, MD, MS, MGH, Chyng-Wen Fwu PhD, Social & Scientific Systems, Inc., Jenna M. Norton MPH, NIH/NIDDK, Paul Eggers PhD, Kevin C. Abbott, MD, MPH, The National Institutes of Health, NIDDK,

Increased racial/ethnic disparities in stroke rates among end-stage renal disease (ESRD) dialysis patients with atrial fibrillation (AF) are partially explained by lower use of oral anticoagulants among Blacks, Hispanics, and Asians. The reasons for these racial disparities in practice are unknown, although the results support an identified need to develop strategies that will maximize stroke prevention in minority populations and resolve system barriers between patient/physician that may block optimal treatment.

Continue reading
NOV
08
0

Adaptive and maladaptive kidney repair models reveal distinct pathways of myeloid and lymphoid cell recruitment and activation

Presenter: Leyuan Xu, PhD, Yale University

Authors: Leyuan Xu, PhD, Yale University, Lloyd G. Cantley MD, FASN, Yale University School of Medicine

LeyuanXuLeyuan XuAbnormal accumulation of macrophages, dendritic cells, and T cells may lead to progressive interstitial fibrosis, sustained inflammation, and kidney injury in the setting of maladaptive kidney repair following IRI. Blocking homing chemokines may serve as a therapeutic target to attenuate CKD progression.

Continue reading
NOV
08
0

Planting a new seed of health

Session: Diet and Acid in CKD: Where Do We Stand?

Subsession: Plant-Based Diets: Pros and Cons in CKD

Presenter: Juan Jesus Carrero, MD, PharmD, PhD, Karolinska Institutet

It’s a hot topic. It’s more than hot. And if the SRO turnout to hear Dr. Carrero discuss plant-based diets in terms of CKD is any indication, the subject is red hot.

The session began with a brief review of current dietary recommendations for those with chronic kidney disease (CKD), which traditionally focuses on quantity — from adjusting protein intake to restricting single micronutrients (sodium, phosphorus, potassium, and calcium) to ensuring sufficient energy.

Continue reading
ukidneyisup